# Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects

> **NCT00888069** · PHASE1 · COMPLETED · sponsor: **OPKO IP Holdings II, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Chronic Kidney Disease
- Secondary Hyperparathyroidism
- Chronic Renal Insufficiency
- Chronic Renal Failure

## Interventions

- **DRUG:** CTAP101 Capsules
- **DRUG:** CTAP101 Injection

## Key facts

- **NCT ID:** NCT00888069
- **Lead sponsor:** OPKO IP Holdings II, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2009-11
- **Final completion:** 2009-12
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2014-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00888069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00888069, "Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00888069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*